首页 > 最新文献

Acta Clinica Belgica最新文献

英文 中文
Factors to take into account when interpreting 25-hydroxy-vitamin D serum levels. 解读 25- 羟维生素 D 血清水平时应考虑的因素。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2024-04-01 Epub Date: 2024-03-07 DOI: 10.1080/17843286.2024.2327218
Joris R Delanghe, Marijn M Speeckaert, Thomas Maenhout

Background: Assessing vitamin D status, typically evaluated using serum or plasma 25-hydroxy vitamin D [25(OH)D] concentration, is complex because of various influencing factors.

Methods: Seasonality significantly affects intra-individual variability in 25(OH)D levels. This variation can be addressed by employing cosinor functions that are tailored to the geographical location of the patient to correct for seasonal effects. In addition to seasonality, genetic factors, such as DBP polymorphism and body composition, particularly adiposity, play crucial roles. Dialysis patients with DBP 2-2 phenotype exhibit higher vitamin D requirements. Genotyping/phenotyping of DBP allows for better tailored vitamin D supplementation. The lipid-soluble nature of vitamin D also interacts with plasma components such as serum triglycerides, which can influence vitamin D measurements. Adiposity, which is negatively correlated with vitamin D concentration, necessitates body mass-based mathematical adjustments for accurate vitamin D assessment in subjects with extreme BMI values.

Conclusions: Accordingly, vitamin D replacement therapy must be personalized, taking into account factors such as body size and seasonal variations, to effectively reach the target serum 25(OH)D concentrations.

背景:评估维生素 D 状态通常使用血清或血浆 25- 羟基维生素 D [25(OH)D] 浓度:评估维生素 D 状态通常使用血清或血浆中 25- 羟基维生素 D [25(OH)D] 的浓度,由于影响因素多种多样,因此评估工作十分复杂:方法:季节性会对 25(OH)D 水平的个体内变异性产生重大影响。这种变异可通过采用适合患者地理位置的 cosinor 函数来校正季节性影响。除季节性外,遗传因素(如 DBP 多态性和身体组成,尤其是脂肪含量)也起着至关重要的作用。具有 DBP 2-2 表型的透析患者对维生素 D 的需求更高。通过对 DBP 进行基因分型/表型分析,可以更有针对性地补充维生素 D。维生素 D 的脂溶性也会与血清甘油三酯等血浆成分相互作用,从而影响维生素 D 的测量。肥胖与维生素 D 浓度呈负相关,因此有必要对体重进行数学调整,以便对体重指数值极高的受试者进行准确的维生素 D 评估:因此,维生素 D 替代疗法必须考虑到体型和季节变化等因素,进行个性化治疗,才能有效达到目标血清 25(OH)D 浓度。
{"title":"Factors to take into account when interpreting 25-hydroxy-vitamin D serum levels.","authors":"Joris R Delanghe, Marijn M Speeckaert, Thomas Maenhout","doi":"10.1080/17843286.2024.2327218","DOIUrl":"10.1080/17843286.2024.2327218","url":null,"abstract":"<p><strong>Background: </strong>Assessing vitamin D status, typically evaluated using serum or plasma 25-hydroxy vitamin D [25(OH)D] concentration, is complex because of various influencing factors.</p><p><strong>Methods: </strong>Seasonality significantly affects intra-individual variability in 25(OH)D levels. This variation can be addressed by employing cosinor functions that are tailored to the geographical location of the patient to correct for seasonal effects. In addition to seasonality, genetic factors, such as DBP polymorphism and body composition, particularly adiposity, play crucial roles. Dialysis patients with DBP 2-2 phenotype exhibit higher vitamin D requirements. Genotyping/phenotyping of DBP allows for better tailored vitamin D supplementation. The lipid-soluble nature of vitamin D also interacts with plasma components such as serum triglycerides, which can influence vitamin D measurements. Adiposity, which is negatively correlated with vitamin D concentration, necessitates body mass-based mathematical adjustments for accurate vitamin D assessment in subjects with extreme BMI values.</p><p><strong>Conclusions: </strong>Accordingly, vitamin D replacement therapy must be personalized, taking into account factors such as body size and seasonal variations, to effectively reach the target serum 25(OH)D concentrations.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140060946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation. MET 抑制剂之间在患有 MET 14 号外显子跳越突变的非小细胞肺癌患者身上没有交叉毒性。
IF 1.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-04-01 Epub Date: 2024-03-18 DOI: 10.1080/17843286.2024.2330137
Ariane Vanderick, Benoît Colinet

Introduction: Selective tyrosine kinase inhibitors are proven effective in patients with non-small lung cancer (NSCLC) with a MET exon 14 skipping mutation.

Case presentation: The patient developed a metastatic lung adenocarcinoma with a MET exon 14 skipping mutation. She was treated with a first 1b MET inhibitor, Capmatinib, but had to stop the drug because of major hepatotoxicity. A few months later, she started Tepotinib, another 1b MET inhibitor with this time, no sign of hepatotoxicity.

Discussion: Adverse events are frequent with 1b MET inhibitors. However, there is a wide interpatient variability. Absence of cross-toxicity between Capmatinib and Tepotinib is misunderstood but can be explained by slight differences in phamarcodynamics and pharmacokinetics. Practitionners have to be warned about severe adverse events to stop or change the drug if necessary.

Conclusion: This is the first case showing the absence of cross-toxicity between 1b MET inhibitors.

导言:选择性酪氨酸激酶抑制剂被证明对MET 14外显子跳越突变的非小肺癌(NSCLC)患者有效:患者为转移性肺腺癌,伴有MET 14外显子跳越突变。她曾接受过 1b MET 抑制剂卡马替尼的治疗,但因出现严重肝毒性而不得不停药。几个月后,她开始服用另一种1b MET抑制剂特罗替尼,这次没有出现肝毒性:讨论:1b MET 抑制剂经常会出现不良反应。讨论:1b MET 抑制剂的不良反应很常见,但患者之间的差异很大。卡马替尼和泰泊替尼之间没有交叉毒性被误解,但这可以用药物动力学和药代动力学的细微差别来解释。必须提醒从业人员注意严重的不良反应,必要时停药或换药:这是首个显示 1b MET 抑制剂之间不存在交叉毒性的病例。
{"title":"Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation.","authors":"Ariane Vanderick, Benoît Colinet","doi":"10.1080/17843286.2024.2330137","DOIUrl":"10.1080/17843286.2024.2330137","url":null,"abstract":"<p><strong>Introduction: </strong>Selective tyrosine kinase inhibitors are proven effective in patients with non-small lung cancer (NSCLC) with a MET exon 14 skipping mutation.</p><p><strong>Case presentation: </strong>The patient developed a metastatic lung adenocarcinoma with a MET exon 14 skipping mutation. She was treated with a first 1b MET inhibitor, Capmatinib, but had to stop the drug because of major hepatotoxicity. A few months later, she started Tepotinib, another 1b MET inhibitor with this time, no sign of hepatotoxicity.</p><p><strong>Discussion: </strong>Adverse events are frequent with 1b MET inhibitors. However, there is a wide interpatient variability. Absence of cross-toxicity between Capmatinib and Tepotinib is misunderstood but can be explained by slight differences in phamarcodynamics and pharmacokinetics. Practitionners have to be warned about severe adverse events to stop or change the drug if necessary.</p><p><strong>Conclusion: </strong>This is the first case showing the absence of cross-toxicity between 1b MET inhibitors.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective evaluation of an intervention bundle on OPAT implementation in a large non-university hospital. 对一家大型非大学医院实施OPAT的一揽子干预措施的回顾性评估。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2024-02-01 Epub Date: 2024-01-02 DOI: 10.1080/17843286.2023.2278237
Laetitia Missiaen, Dirk Vogelaers, Pieter-Jan De Roo, Frederik Van Hoecke, Bert Vanmierlo, Tine Ravelingien, Jodie Langbeen

Objectives: Optimization of outpatient parenteral antimicrobial therapy (OPAT) requires interdisciplinarity and an operational algorithm. This report retrospectively assesses the impact of a multimodal quality-enhancement intervention bundle on the implementation rate, efficacy, and safety of a home OPAT program in a Belgian large community-based hospital.

Methods: OPAT recipients between 1 March 2019 and 30 June 2022 were included. The OPAT trajectories were divided into pre-intervention (from 1 March 2019 to 31 October 2020) and post-intervention (from 1 November 2020 to 30 June 2022) groups. The quality-enhancement intervention bundle consisted of the involvement of an infectious disease specialist, revision and implementation of a state-of-the-art prosthetic joint infection diagnosis and treatment protocol, weekly multidisciplinary discussion of all prosthetic joint infections, revision of the OPAT algorithm, and the introduction of teicoplanin as an OPAT-convenient antimicrobial.

Results: Eighty-five patients were included in a total of 96 OPAT trajectories (n = 33 pre-intervention; n = 63 post-intervention). After the intervention, the number of OPAT trajectories nearly doubled. The number of patients with a recurrent infection within 6 months after OPAT completion decreased 15%. The overall 6-month mortality and readmission rates during OPAT treatment decreased 8% and 10%, respectively. Mortality during OPAT treatment did not change. These differences between pre- and post-intervention did not achieve statistical significance, despite the higher risk for complications in the post-intervention group because of increased infection complexity and required treatment duration.

Conclusion: Within a Belgian, single, large community-based hospital, a multimodal intervention bundle resulted in increases in OPAT implementation, infection complexity, and required treatment durations without statistically significant differences in outcomes.

目的:优化门诊肠外抗菌治疗(OPAT)需要跨学科和操作算法。本报告回顾性评估了多模式质量增强干预包对比利时一家大型社区医院家庭OPAT项目实施率、疗效和安全性的影响。方法:纳入2019年3月1日至2022年6月30日期间的OPAT接受者。OPAT轨迹分为干预前(从2019年3月1日至2020年10月31日)和干预后(从2020年11月1日到2022年6月30日)两组。质量提高干预包包括传染病专家的参与,修订和实施最先进的人工关节感染诊断和治疗方案,每周对所有人工关节感染进行多学科讨论,修订OPAT算法,以及引入替考拉宁作为OPAT方便的抗菌剂。结果:85名患者被纳入总共96个OPAT轨迹(n = 33预干预;n = 63干预后)。干预后,OPAT轨迹的数量几乎翻了一番。6个月内复发感染的患者人数 OPAT完成后的几个月减少了15%。OPAT治疗期间6个月的总死亡率和再入院率分别下降了8%和10%。OPAT治疗期间的死亡率没有变化。干预前和干预后的这些差异没有达到统计学意义,尽管干预后组由于感染复杂性增加和所需治疗时间增加而出现并发症的风险更高。结论:在比利时一家单一的大型社区医院内,多模式干预组合导致OPAT实施、感染复杂性和所需治疗时间的增加,而结果没有统计学上的显著差异。
{"title":"Retrospective evaluation of an intervention bundle on OPAT implementation in a large non-university hospital.","authors":"Laetitia Missiaen, Dirk Vogelaers, Pieter-Jan De Roo, Frederik Van Hoecke, Bert Vanmierlo, Tine Ravelingien, Jodie Langbeen","doi":"10.1080/17843286.2023.2278237","DOIUrl":"10.1080/17843286.2023.2278237","url":null,"abstract":"<p><strong>Objectives: </strong>Optimization of outpatient parenteral antimicrobial therapy (OPAT) requires interdisciplinarity and an operational algorithm. This report retrospectively assesses the impact of a multimodal quality-enhancement intervention bundle on the implementation rate, efficacy, and safety of a home OPAT program in a Belgian large community-based hospital.</p><p><strong>Methods: </strong>OPAT recipients between 1 March 2019 and 30 June 2022 were included. The OPAT trajectories were divided into pre-intervention (from 1 March 2019 to 31 October 2020) and post-intervention (from 1 November 2020 to 30 June 2022) groups. The quality-enhancement intervention bundle consisted of the involvement of an infectious disease specialist, revision and implementation of a state-of-the-art prosthetic joint infection diagnosis and treatment protocol, weekly multidisciplinary discussion of all prosthetic joint infections, revision of the OPAT algorithm, and the introduction of teicoplanin as an OPAT-convenient antimicrobial.</p><p><strong>Results: </strong>Eighty-five patients were included in a total of 96 OPAT trajectories (<i>n</i> = 33 pre-intervention; <i>n</i> = 63 post-intervention). After the intervention, the number of OPAT trajectories nearly doubled. The number of patients with a recurrent infection within 6 months after OPAT completion decreased 15%. The overall 6-month mortality and readmission rates during OPAT treatment decreased 8% and 10%, respectively. Mortality during OPAT treatment did not change. These differences between pre- and post-intervention did not achieve statistical significance, despite the higher risk for complications in the post-intervention group because of increased infection complexity and required treatment duration.</p><p><strong>Conclusion: </strong>Within a Belgian, single, large community-based hospital, a multimodal intervention bundle resulted in increases in OPAT implementation, infection complexity, and required treatment durations without statistically significant differences in outcomes.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Work stress and burnout among emergency physicians: a systematic review of last 10 years of research. 急诊医生的工作压力和倦怠:对过去10年研究的系统回顾。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2024-02-01 Epub Date: 2024-01-02 DOI: 10.1080/17843286.2023.2273611
F Somville, P Van Bogaert, B Wellens, H De Cauwer, E Franck

Aim of the study: First, to provide a synthesis and analysis of available scientific literature regarding the level of work stress and burnout among emergency physicians. Second, to identify the effect of the specific work situation-related factors.

Methods: A systematic search was performed in NCBI PubMed and Embase. Comparative primary studies, both systematic review and cross-sectional, quantifying burnout in emergency physicians were included. Only studies published between 2011 and 2022 were retained. Synonym sets were compiled for the search key for 'burnout & stress', 'emergency', 'physician' and 'burnout & posttraumatic stress disorder'.

Results: Thirty-five papers were retained for further research. Emergency physicians scored significantly higher for all dimensions of burnout compared to other healthcare professions. Significant correlations for burnout were found with work characteristic and organizational factors. Critical incidents and aggression were identified as the most important acute work characteristics and organizational factors impacting emergency physician's mental wellbeing including the development of posttraumatic stress disorder. Moreover, personal factors such as age, personality, and coping strategies also play an important role in the development of burnout as well as work-related trauma.

Conclusion: Available studies show that emergency physicians report higher scores of emotional exhaustion and depersonalization when compared to other healthcare professionals. Work characteristics contribute to this, but work-related traumatic incidents and aggression are important determinants. Personal characteristics such as age, personality type D, previous experiences and coping strategies seem to be determining factors likewise. Emergency physicians showed a high risk for developing burnout and work stress-related problems.

本研究的目的:首先,综合和分析现有的关于急诊医生工作压力和倦怠水平的科学文献。其次,识别影响具体工作情境的相关因素。方法:在NCBI PubMed和Embase中进行系统检索。包括系统回顾和横断面的比较性初级研究,量化急诊医生的倦怠。只保留了2011年至2022年间发表的研究。为“倦怠与压力”、“急诊”、“医生”和“倦怠与创伤后应激障碍”的搜索关键字编制了同义词集。结果:35篇论文被保留以供进一步研究。与其他医疗专业相比,急诊医生在倦怠的各个方面的得分都明显更高。工作倦怠与工作特点和组织因素存在显著相关性。危重事件和攻击被确定为影响急诊医生心理健康的最重要的急性工作特征和组织因素,包括创伤后应激障碍的发展。此外,年龄、性格和应对策略等个人因素在职业倦怠和工作创伤的发展中也起着重要作用。结论:现有研究表明,与其他医疗保健专业人员相比,急诊医生报告的情绪衰竭和人格解体得分更高。工作特点促成了这一点,但与工作相关的创伤事件和攻击性是重要的决定因素。年龄、D型人格、以往经历和应对策略等个人特征似乎也是决定因素。急诊医生表现出出现倦怠和工作压力相关问题的高风险。
{"title":"Work stress and burnout among emergency physicians: a systematic review of last 10 years of research.","authors":"F Somville, P Van Bogaert, B Wellens, H De Cauwer, E Franck","doi":"10.1080/17843286.2023.2273611","DOIUrl":"10.1080/17843286.2023.2273611","url":null,"abstract":"<p><strong>Aim of the study: </strong>First, to provide a synthesis and analysis of available scientific literature regarding the level of work stress and burnout among emergency physicians. Second, to identify the effect of the specific work situation-related factors.</p><p><strong>Methods: </strong>A systematic search was performed in NCBI PubMed and Embase. Comparative primary studies, both systematic review and cross-sectional, quantifying burnout in emergency physicians were included. Only studies published between 2011 and 2022 were retained. Synonym sets were compiled for the search key for 'burnout & stress', 'emergency', 'physician' and 'burnout & posttraumatic stress disorder'.</p><p><strong>Results: </strong>Thirty-five papers were retained for further research. Emergency physicians scored significantly higher for all dimensions of burnout compared to other healthcare professions. Significant correlations for burnout were found with work characteristic and organizational factors. Critical incidents and aggression were identified as the most important acute work characteristics and organizational factors impacting emergency physician's mental wellbeing including the development of posttraumatic stress disorder. Moreover, personal factors such as age, personality, and coping strategies also play an important role in the development of burnout as well as work-related trauma.</p><p><strong>Conclusion: </strong>Available studies show that emergency physicians report higher scores of emotional exhaustion and depersonalization when compared to other healthcare professionals. Work characteristics contribute to this, but work-related traumatic incidents and aggression are important determinants. Personal characteristics such as age, personality type D, previous experiences and coping strategies seem to be determining factors likewise. Emergency physicians showed a high risk for developing burnout and work stress-related problems.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54231802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to treat the climate and nature crisis as one indivisible global health emergency. 是时候将气候和自然危机作为一个不可分割的全球健康紧急事件来对待了。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2024-02-01 Epub Date: 2024-01-02 DOI: 10.1080/17843286.2023.2276496
Kamran Abbasi, Parveen Ali, Virginia Barbour, Thomas Benfield, Kirsten Bibbins-Domingo, Gregory E Erhabor, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Robert Mash, Peush Sahni, Wadeia Mohammad Sharief, Paul Yonga, Chris Zielinski
{"title":"Time to treat the climate and nature crisis as one indivisible global health emergency.","authors":"Kamran Abbasi, Parveen Ali, Virginia Barbour, Thomas Benfield, Kirsten Bibbins-Domingo, Gregory E Erhabor, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Robert Mash, Peush Sahni, Wadeia Mohammad Sharief, Paul Yonga, Chris Zielinski","doi":"10.1080/17843286.2023.2276496","DOIUrl":"10.1080/17843286.2023.2276496","url":null,"abstract":"","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139089134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart failure with severely reduced ejection fraction after liver transplantation: a case report and review of the literature. 肝移植后射血分数严重降低的心力衰竭:一例报告和文献复习。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2024-02-01 Epub Date: 2024-01-02 DOI: 10.1080/17843286.2023.2278240
Dorien Pint, Andreas B Gevaert, Thomas Vanwolleghem, Thiery Chapelle, Karolien Dams

Background: Liver transplantation (LT) is a strenuous event for the cardiovascular system. Cardiovascular events (CVE), including heart failure (HF), arrhythmias and myocardial ischemia, are important causes of peri- and post-liver transplantation morbidity and mortality.

Case presentation: We describe the case of a 45-year-old male patient who developed heart failure with severely reduced ejection fraction (HFrEF) after receiving liver transplantation (LT) for end-stage post-alcoholic liver cirrhosis. Preoperative transthoracic echocardiography (TTE) demonstrated borderline left ventricular ejection fraction (LVEF) of 50% and diastolic dysfunction grade 2. On coronary angiography, the patient had no coronary stenoses. Persistent vasopressor need, increasing creatinine levels and progressive pleural effusion characterized the early postoperative period. TTE on postoperative day 6 revealed a new finding of a markedly reduced LVEF of 15%, accompanied by a discrete increase in hs-TnI and CK-MB without electrocardiographic (ECG) ST-T abnormalities. LVEF did not recover completely (EF 45%) during follow-up. The patient had a sudden death 4.5 months post-liver transplantation.

Conclusion: Our case demonstrates that the risk of post-LT systolic dysfunction is not excluded by preoperative resting examinations within normal range and highlights the need for preoperative cardiac stress assessment (e.g. dobutamine echocardiography or stress cardiac magnetic resonance imaging) before LT. In addition, patients on a liver-transplant waiting list with cardiac dysfunction should be followed by a multidisciplinary team including a dedicated cardiology team experienced in managing liver-related cardiac pathology.

背景:肝移植(LT)对心血管系统来说是一项艰巨的任务。心血管事件(CVE),包括心力衰竭(HF)、心律失常和心肌缺血,是肝移植前后发病率和死亡率的重要原因。病例介绍:我们描述了一例45岁的男性患者,他在接受肝移植(LT)治疗终末期酒精性肝硬化后,出现射血分数严重降低的心力衰竭。术前经胸超声心动图(TTE)显示临界左心室射血分数(LVEF)为50%,舒张功能障碍为2级。在冠状动脉造影中,患者没有冠状动脉狭窄。术后早期持续需要血管升压药、肌酸酐水平升高和进行性胸腔积液。术后第6天经胸超声心动图显示,左心室射血分数显著降低15%,伴有hs-TnI和CK-MB的离散增加,没有心电图(ECG)ST-T异常。随访期间LVEF未完全恢复(EF为45%)。病人突然死亡4.5 肝移植后数月。结论:我们的病例表明,在正常范围内进行术前静息检查并不能排除LT后收缩功能障碍的风险,并强调了在LT前进行术前心脏压力评估(如多巴酚丁胺超声心动图或压力性心脏磁共振成像)的必要性。此外,肝移植等待名单上有心脏功能障碍的患者应该由一个多学科团队跟进,其中包括一个在管理肝脏相关心脏病理方面经验丰富的专门心脏病学团队。
{"title":"Heart failure with severely reduced ejection fraction after liver transplantation: a case report and review of the literature.","authors":"Dorien Pint, Andreas B Gevaert, Thomas Vanwolleghem, Thiery Chapelle, Karolien Dams","doi":"10.1080/17843286.2023.2278240","DOIUrl":"10.1080/17843286.2023.2278240","url":null,"abstract":"<p><strong>Background: </strong>Liver transplantation (LT) is a strenuous event for the cardiovascular system. Cardiovascular events (CVE), including heart failure (HF), arrhythmias and myocardial ischemia, are important causes of peri- and post-liver transplantation morbidity and mortality.</p><p><strong>Case presentation: </strong>We describe the case of a 45-year-old male patient who developed heart failure with severely reduced ejection fraction (HFrEF) after receiving liver transplantation (LT) for end-stage post-alcoholic liver cirrhosis. Preoperative transthoracic echocardiography (TTE) demonstrated borderline left ventricular ejection fraction (LVEF) of 50% and diastolic dysfunction grade 2. On coronary angiography, the patient had no coronary stenoses. Persistent vasopressor need, increasing creatinine levels and progressive pleural effusion characterized the early postoperative period. TTE on postoperative day 6 revealed a new finding of a markedly reduced LVEF of 15%, accompanied by a discrete increase in hs-TnI and CK-MB without electrocardiographic (ECG) ST-T abnormalities. LVEF did not recover completely (EF 45%) during follow-up. The patient had a sudden death 4.5 months post-liver transplantation.</p><p><strong>Conclusion: </strong>Our case demonstrates that the risk of post-LT systolic dysfunction is not excluded by preoperative resting examinations within normal range and highlights the need for preoperative cardiac stress assessment (e.g. dobutamine echocardiography or stress cardiac magnetic resonance imaging) before LT. In addition, patients on a liver-transplant waiting list with cardiac dysfunction should be followed by a multidisciplinary team including a dedicated cardiology team experienced in managing liver-related cardiac pathology.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human urea production, an ignored factor in the nitrogen debate. 人体尿素产量,在氮争论中一个被忽视的因素。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2024-02-01 Epub Date: 2024-01-02 DOI: 10.1080/17843286.2023.2290412
Joris Delanghe

A public debate idealing with nitrogen (N) emissions is ongoing. Government reports use models in which the major N producers are agriculture and industry. Flemish NOx emission amounted to 26.4 kt N accompanied by an ammonia emission of 34.0 kt N. Major sources of Flemish N emission are agriculture (59% of total emission) and transport (21%); 95 percent of the ammonia emission is reported to come from agriculture. In this government's view, it looks like Flanders is unpopulated. In Flanders, 6,800,000 inhabitants show an average urea production of 20 g/day, or 3.65 kg N/year. This urea production eventually ends up in wastewaters as ammonia. Human urea production represents the grand total of 24.8 kl N/year. However, this contribution is made invisible in the statistics. Flemish reports mention a grand total of 33 kt/year, so Flemish numbers appear to be incomplete. Human production has not been taken into account. When calculating human N excretion in Flanders, 24.8 kt N/12.322 km2 is obtained, corresponding to an additional N load of ± 20 kg/ha. Implementing human N excretion into the calculation thoroughly changes the situation: adding human N production results in peak loads of 40 kg N/ha. The human nitrogen input is comparable with the heavily criticized contribution by agriculture. Policy should take into account the real size of the problem and not selectively focus on partial problems.

一场关于氮(N)排放的公众辩论正在进行中。政府报告使用的模型中,主要的氮生产者是农业和工业。佛兰德氮氧化物排放量为26.4 kt N,氨排放量为34.0 kt N。佛兰德氮氧化物排放的主要来源是农业(占总排放量的59%)和运输(21%);据报道,95%的氨排放来自农业。在本届政府看来,佛兰德斯似乎无人居住。在佛兰德斯,680万居民的平均尿素产量为20克/天,即3.65千克/年。这种尿素的生产最终以氨的形式进入废水。人体尿素产量为每年24.8千升氮。然而,这种贡献在统计数据中是不可见的。佛兰德语的报告提到每年总共有33千吨,所以佛兰德语的数字似乎是不完整的。人类生产并没有被考虑在内。在计算法兰德斯地区人类氮排泄量时,得到24.8 kt N/12.322 km2,对应于±20 kg/ha的额外氮负荷。将人体N排泄量纳入计算,彻底改变了这种情况:增加人体N排泄量,峰值负荷为40 kg N/ha。人类氮的投入可与受到严厉批评的农业贡献相媲美。政策应该考虑到问题的实际规模,而不是选择性地关注局部问题。
{"title":"Human urea production, an ignored factor in the nitrogen debate.","authors":"Joris Delanghe","doi":"10.1080/17843286.2023.2290412","DOIUrl":"10.1080/17843286.2023.2290412","url":null,"abstract":"<p><p>A public debate idealing with nitrogen (N) emissions is ongoing. Government reports use models in which the major N producers are agriculture and industry. Flemish NOx emission amounted to 26.4 kt N accompanied by an ammonia emission of 34.0 kt N. Major sources of Flemish N emission are agriculture (59% of total emission) and transport (21%); 95 percent of the ammonia emission is reported to come from agriculture. In this government's view, it looks like Flanders is unpopulated. In Flanders, 6,800,000 inhabitants show an average urea production of 20 g/day, or 3.65 kg N/year. This urea production eventually ends up in wastewaters as ammonia. Human urea production represents the grand total of 24.8 kl N/year. However, this contribution is made invisible in the statistics. Flemish reports mention a grand total of 33 kt/year, so Flemish numbers appear to be incomplete. Human production has not been taken into account. When calculating human N excretion in Flanders, 24.8 kt N/12.322 km2 is obtained, corresponding to an additional N load of ± 20 kg/ha. Implementing human N excretion into the calculation thoroughly changes the situation: adding human N production results in peak loads of 40 kg N/ha. The human nitrogen input is comparable with the heavily criticized contribution by agriculture. Policy should take into account the real size of the problem and not selectively focus on partial problems.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138478938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken. 弗拉芒罕见结缔组织疾病网络(CTD):系统性硬化症患者路径。已采取的初步措施。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2024-02-01 Epub Date: 2024-01-02 DOI: 10.1080/17843286.2023.2280737
Y Piette, F Van den Bossche, J Aerts, N Aerts, S Ajeganova, V Badot, N Berghen, D Blockmans, G Brusselle, N Caeyers, M De Decker, P De Haes, C De Cock, F De Keyser, E De Langhe, M Delcroix, H De Nutte, M De Pauw, A Depicker, A De Sutter, J De Sutter, T Du Four, C Frank, J Goubau, J Guiot, J Gutermuth, L Heeman, F Houssiau, I Hennes, J Lenaerts, A Lintermans, B Loeys, H Luyten, B Maeyaert, F Malfait, A Moeyersoons, Y Mostmans, J Nijs, B Poppe, K Polfliet, D Ruttens, V Sabato, E Schoeters, H Slabbynck, A Stuer, F Tamirou, Kristof Thevissen, G Van Kersschaever, B Vanneuville, J Van Offel, M Vanthuyne, J Van Wabeke, C Verbist, I Vos, R Westhovens, W Wuyts, J Yserbyt, V Smith

Despite the low prevalence of each rare disease, the total burden is high. Patients with rare diseases encounter numerous barriers, including delayed diagnosis and limited access to high-quality treatments. In order to tackle these challenges, the European Commission launched the European Reference Networks (ERNs), cross-border networks of healthcare providers and patients representatives. In parallel, the aims and structure of these ERNs were translated at the federal and regional levels, resulting in the creation of the Flemish Network of Rare Diseases. In line with the mission of the ERNs and to ensure equal access to care, we describe as first patient pathways for systemic sclerosis (SSc), as a pilot model for other rare connective and musculoskeletal diseases. Consensus was reached on following key messages: 1. Patients with SSc should have multidisciplinary clinical and investigational evaluations in a tertiary reference expert centre at baseline, and subsequently every three to 5 years. Intermediately, a yearly clinical evaluation should be provided in the reference centre, whilst SSc technical evaluations are permissionably executed in a centre that follows SSc-specific clinical practice guidelines. In between, monitoring can take place in secondary care units, under the condition that qualitative examinations and care including interactive multidisciplinary consultations can be provided. 2. Patients with early diffuse cutaneous SSc, (progressive) interstitial lung disease and/or pulmonary arterial hypertension should undergo regular evaluations in specialised tertiary care reference institutions. 3. Monitoring of patients with progressive interstitial lung disease and/or pulmonary (arterial) hypertension will be done in agreement with experts of ERN LUNG.

尽管每种罕见病的发病率都很低,但总负担却很重。罕见病患者会遇到许多障碍,包括诊断延误和获得高质量治疗的机会有限。为了应对这些挑战,欧盟委员会启动了欧洲参考网络 (ERN),这是一个由医疗服务提供者和患者代表组成的跨境网络。与此同时,这些欧洲参考网络的目标和结构也在联邦和地区层面得到了体现,弗拉芒罕见病网络由此诞生。根据 ERNs 的使命,并为了确保平等获得医疗服务,我们首先描述了系统性硬化症(SSc)的患者路径,并将其作为其他罕见结缔组织和肌肉骨骼疾病的试点模式。我们就以下关键信息达成了共识:1.1. 系统性硬化症患者应在三级参考专家中心接受多学科临床和研究评估。在此期间,参考中心应每年进行一次临床评估,而 SSc 技术评估则可在遵循 SSc 特定临床实践指南的中心进行。在此期间,可在二级医疗单位进行监测,条件是提供定性检查和护理,包括互动式多学科会诊。2.2. 早期弥漫性皮肤 SSc、(进行性)间质性肺病和/或肺动脉高压患者应在专门的三级医疗机构接受定期评估。3.3. 进展性间质性肺病和/或肺(动脉)高血压患者的监测工作将与 ERN LUNG 的专家协商进行。
{"title":"Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken.","authors":"Y Piette, F Van den Bossche, J Aerts, N Aerts, S Ajeganova, V Badot, N Berghen, D Blockmans, G Brusselle, N Caeyers, M De Decker, P De Haes, C De Cock, F De Keyser, E De Langhe, M Delcroix, H De Nutte, M De Pauw, A Depicker, A De Sutter, J De Sutter, T Du Four, C Frank, J Goubau, J Guiot, J Gutermuth, L Heeman, F Houssiau, I Hennes, J Lenaerts, A Lintermans, B Loeys, H Luyten, B Maeyaert, F Malfait, A Moeyersoons, Y Mostmans, J Nijs, B Poppe, K Polfliet, D Ruttens, V Sabato, E Schoeters, H Slabbynck, A Stuer, F Tamirou, Kristof Thevissen, G Van Kersschaever, B Vanneuville, J Van Offel, M Vanthuyne, J Van Wabeke, C Verbist, I Vos, R Westhovens, W Wuyts, J Yserbyt, V Smith","doi":"10.1080/17843286.2023.2280737","DOIUrl":"10.1080/17843286.2023.2280737","url":null,"abstract":"<p><p>Despite the low prevalence of each rare disease, the total burden is high. Patients with rare diseases encounter numerous barriers, including delayed diagnosis and limited access to high-quality treatments. In order to tackle these challenges, the European Commission launched the European Reference Networks (ERNs), cross-border networks of healthcare providers and patients representatives. In parallel, the aims and structure of these ERNs were translated at the federal and regional levels, resulting in the creation of the Flemish Network of Rare Diseases. In line with the mission of the ERNs and to ensure equal access to care, we describe as first patient pathways for systemic sclerosis (SSc), as a pilot model for other rare connective and musculoskeletal diseases. Consensus was reached on following key messages: 1. Patients with SSc should have multidisciplinary clinical and investigational evaluations in a tertiary reference expert centre at baseline, and subsequently every three to 5 years. Intermediately, a yearly clinical evaluation should be provided in the reference centre, whilst SSc technical evaluations are permissionably executed in a centre that follows SSc-specific clinical practice guidelines. In between, monitoring can take place in secondary care units, under the condition that qualitative examinations and care including interactive multidisciplinary consultations can be provided. 2. Patients with early diffuse cutaneous SSc, (progressive) interstitial lung disease and/or pulmonary arterial hypertension should undergo regular evaluations in specialised tertiary care reference institutions. 3. Monitoring of patients with progressive interstitial lung disease and/or pulmonary (arterial) hypertension will be done in agreement with experts of ERN LUNG.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138805898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acquired factor X deficiency in a multiple myeloma without amyloidosis: a case report. 无淀粉样变性的多发性骨髓瘤获得性X因子缺乏症一例报告。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2023-12-01 Epub Date: 2023-10-16 DOI: 10.1080/17843286.2023.2265650
Amber Coussee, Gudrun Alliet, Anne-Sophie Hervent, Liesbeth Vynckier, Jan Emmerechts, Sam Van Hecke, Lies Persijn

Background: Multiple myeloma is one of the most common hematologic malignancies. Acquired factor X deficiencies are often observed in primary (AL) amyloidosis and rarely in multiple myeloma.

Objective: We report a case of an acquired factor X deficiency in a patient with a newly diagnosed IgA lambda multiple myeloma, without any evidence of concomitant amyloidosis.

Methods: We present the patient's medical history, clinical and physical examinations, laboratory analysis, and outcome.

Results: A 76-year-old male presented at the emergency department with ongoing gingival bleeding. Several analytical problems with blood sample analysis arose, which eventually led to the diagnosis of a multiple myeloma. Further exploration revealed an acquired factor X deficiency, explaining the ongoing bleeding. There was no evidence of concomitant amyloidosis. The multiple myeloma was treated, leading to complete remission of the malignancy and bleeding tendency.

Conclusion: While coagulopathy is rarely observed in patients diagnosed with multiple myeloma, considering an acquired factor X deficiency becomes relevant when such patient present with bleeding diathesis.

背景:多发性骨髓瘤是最常见的血液系统恶性肿瘤之一。获得性X因子缺乏常见于原发性(AL)淀粉样变性,很少见于多发性骨髓瘤。目的:我们报告一例新诊断的IgAλ多发性骨髓瘤患者的获得性X因子缺乏症,没有任何伴发淀粉样变性的证据。方法:介绍患者的病史、临床和体格检查、实验室分析和结果。结果:一名76岁男性因牙龈持续出血到急诊科就诊。血液样本分析出现了几个分析问题,最终诊断为多发性骨髓瘤。进一步的探索揭示了后天性X因子缺乏,解释了持续出血的原因。没有伴发淀粉样变性的证据。治疗了多发性骨髓瘤,使恶性肿瘤和出血倾向完全缓解。结论:虽然在诊断为多发性骨髓瘤的患者中很少观察到凝血障碍,但当这些患者具有出血素质时,考虑到获得性X因子缺乏是相关的。
{"title":"Acquired factor X deficiency in a multiple myeloma without amyloidosis: a case report.","authors":"Amber Coussee,&nbsp;Gudrun Alliet,&nbsp;Anne-Sophie Hervent,&nbsp;Liesbeth Vynckier,&nbsp;Jan Emmerechts,&nbsp;Sam Van Hecke,&nbsp;Lies Persijn","doi":"10.1080/17843286.2023.2265650","DOIUrl":"10.1080/17843286.2023.2265650","url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma is one of the most common hematologic malignancies. Acquired factor X deficiencies are often observed in primary (AL) amyloidosis and rarely in multiple myeloma.</p><p><strong>Objective: </strong>We report a case of an acquired factor X deficiency in a patient with a newly diagnosed IgA lambda multiple myeloma, without any evidence of concomitant amyloidosis.</p><p><strong>Methods: </strong>We present the patient's medical history, clinical and physical examinations, laboratory analysis, and outcome.</p><p><strong>Results: </strong>A 76-year-old male presented at the emergency department with ongoing gingival bleeding. Several analytical problems with blood sample analysis arose, which eventually led to the diagnosis of a multiple myeloma. Further exploration revealed an acquired factor X deficiency, explaining the ongoing bleeding. There was no evidence of concomitant amyloidosis. The multiple myeloma was treated, leading to complete remission of the malignancy and bleeding tendency.</p><p><strong>Conclusion: </strong>While coagulopathy is rarely observed in patients diagnosed with multiple myeloma, considering an acquired factor X deficiency becomes relevant when such patient present with bleeding diathesis.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41148842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute stroke in patients taking an oral anticoagulant: impact of clinical pharmacist's intervention on pharmacovigilance reporting. 口服抗凝血剂患者的急性卒中:临床药剂师干预对药物警戒报告的影响。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2023-12-01 Epub Date: 2023-10-16 DOI: 10.1080/17843286.2023.2261716
Eve-Marie Thillard, Chloé Rousselière, Johana Béné, François Caparros, Marie Bodenant, Pascal Odou, Sophie Gautier, Bertrand Décaudin

Introduction: Ischemic or hemorrhagic stroke can occur to patients treated with oral anticoagulants (OAC), through lack of effectiveness or overdosing.

Objective: To evaluate the impact of clinical pharmacist's intervention on pharmacovigilance (PV) reporting for OAC-treated patients hospitalized for stroke.

Methods: Monocentric prospective study in which a clinical pharmacist's intervention was performed in a stroke unit, with a focus on patients treated by OAC prior admission. A PV report was made with all data collected for cases of stroke suspected to be related to OAC therapy. Data provided by pharmacist were compared with data initially available in the patient's electronic medical records. PV reports with pharmacist intervention were compared to those without.

Results: During the study period, 48 patients were included in the study: 43 (89.6%) ischemic strokes with an embolic or unknown etiology, four hemorrhage strokes (8.33%), and one medication error (2.08%). A clinical pharmacist intervention was performed for 19 patients (39.6%) and provided significant additional data in all of them (100%). The information was related to adherence to treatment for 17 cases (89.5%), OAC's initial prescription date for 11 cases (57.9%) and identifying event(s) that could have interfered with the efficacy of the OAC in five cases (26.3%). For patients with pharmacist intervention, PV reports were significantly more informative in terms of date's introduction of anticoagulant, adherence to treatment, reference to weight change or concomitant event.

Conclusions: clinical pharmacist's intervention with patients taking oral anticoagulants and hospitalized for acute stroke contributes to collect high-quality data for pharmacovigilance reporting.

引言:口服抗凝血剂(OAC)治疗的患者可能因缺乏疗效或服用过量而发生缺血性或出血性中风。目的:评估临床药剂师的干预对OAC治疗的脑卒中住院患者药物警戒(PV)报告的影响。方法:单中心前瞻性研究,临床药剂师在中风病房进行干预,重点关注入院前接受OAC治疗的患者。PV报告收集了疑似与OAC治疗相关的中风病例的所有数据。药剂师提供的数据与患者电子医疗记录中最初可用的数据进行了比较。将有药剂师干预的PV报告与没有药剂师干预的报告进行比较。结果:在研究期间,48名患者被纳入研究:43例(89.6%)病因不明的缺血性中风,4例出血性中风(8.33%),1例药物错误(2.08%)。对19例(39.6%)患者进行了临床药剂师干预,并为所有患者(100%)提供了重要的额外数据。这些信息与17例(89.5%)的治疗依从性、11例(57.9%)的OAC初始处方日期以及5例(26.3%)可能干扰OAC疗效的确定事件有关。对于药剂师干预的患者,PV报告在日期引入抗凝剂、治疗依从性,指体重变化或伴随事件。结论:临床药剂师对服用口服抗凝剂和因急性中风住院的患者进行干预,有助于收集高质量的药物警戒报告数据。
{"title":"Acute stroke in patients taking an oral anticoagulant: impact of clinical pharmacist's intervention on pharmacovigilance reporting.","authors":"Eve-Marie Thillard,&nbsp;Chloé Rousselière,&nbsp;Johana Béné,&nbsp;François Caparros,&nbsp;Marie Bodenant,&nbsp;Pascal Odou,&nbsp;Sophie Gautier,&nbsp;Bertrand Décaudin","doi":"10.1080/17843286.2023.2261716","DOIUrl":"10.1080/17843286.2023.2261716","url":null,"abstract":"<p><strong>Introduction: </strong>Ischemic or hemorrhagic stroke can occur to patients treated with oral anticoagulants (OAC), through lack of effectiveness or overdosing.</p><p><strong>Objective: </strong>To evaluate the impact of clinical pharmacist's intervention on pharmacovigilance (PV) reporting for OAC-treated patients hospitalized for stroke.</p><p><strong>Methods: </strong>Monocentric prospective study in which a clinical pharmacist's intervention was performed in a stroke unit, with a focus on patients treated by OAC prior admission. A PV report was made with all data collected for cases of stroke suspected to be related to OAC therapy. Data provided by pharmacist were compared with data initially available in the patient's electronic medical records. PV reports with pharmacist intervention were compared to those without.</p><p><strong>Results: </strong>During the study period, 48 patients were included in the study: 43 (89.6%) ischemic strokes with an embolic or unknown etiology, four hemorrhage strokes (8.33%), and one medication error (2.08%). A clinical pharmacist intervention was performed for 19 patients (39.6%) and provided significant additional data in all of them (100%). The information was related to adherence to treatment for 17 cases (89.5%), OAC's initial prescription date for 11 cases (57.9%) and identifying event(s) that could have interfered with the efficacy of the OAC in five cases (26.3%). For patients with pharmacist intervention, PV reports were significantly more informative in terms of date's introduction of anticoagulant, adherence to treatment, reference to weight change or concomitant event.</p><p><strong>Conclusions: </strong>clinical pharmacist's intervention with patients taking oral anticoagulants and hospitalized for acute stroke contributes to collect high-quality data for pharmacovigilance reporting.</p>","PeriodicalId":48865,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Clinica Belgica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1